Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy

Critical Reviews in Oncology/Hematology

Volumn 74, Issue 3, 2010, Pages 203-210

  Aapro, Matti ^a   Schwenkglenks, Matthias ^b   Lyman, Gary H ^c   Lopez Pousa, Antonio ^d   Lawrinson, Susan ^e   Skacel, Tomas ^f,g   Bacon, Pamela ^f   von Minckwitz, Gunter ^h  

^a CLINIQUE DE GENOLIER   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^e AMGEN LTD   (United Kingdom)

^f AMGEN INC   (United States)

^g UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^h GOETHE UNIVERSITY   (Germany)

Author keywords

Breast cancer; Chemotherapy; Elderly; Febrile neutropenia; G CSF; Pegfilgrastim; Primary prophylaxis

Indexed keywords

ANTINEOPLASTIC AGENT; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

AGED; ANEMIA; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CLINICAL TRIAL; CONTROLLED STUDY; ELDERLY CARE; FEBRILE NEUTROPENIA; FEMALE; HOSPITALIZATION; HUMAN; INCIDENCE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; REVIEW; THROMBOCYTOPENIA;

AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; FILGRASTIM; HUMANS; NEUTROPENIA;

EID: 77953356096     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2009.06.004     Document Type: Review

References (35)

1. Kuderer N.M., Dale D.C., Crawford J., Cosler L.E., Lyman G.H. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006, 106:2258-2266.
2. Kuderer N.M., Dale D.C., Crawford J., Lyman G.H. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007, 25:3158-3167.
3. Bonadonna G., Moliterni A., Zambetti M., et al. 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ 2005, 330:217.
4. Chirivella I., Bermejo B., Insa A., et al. Impact of chemotherapy dose-related factors on survival in breast cancer patients treated with adjuvant anthracycline-based chemotherapy. J Clin Oncol 2006, 18S:668. [Abstract].
5. Szutowicz E., Radecka B., Dziadziuszko R., Jassem J. Relative dose intensity (RDI) relevance in adjuvant CMF chemotherapy of breast cancer. Eur J Cancer Suppl 2006, 4:155. [Abstract 366].
6. Aapro M.S., Cameron D.A., Pettengell R., et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006, 42:2433-2453.
7. Hryniuk W., Frei E., Wright F.A. A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: summation dose-intensity. J Clin Oncol 1998, 16:3137-3147.
8. Smith T.J., Khatcheressian J., Lyman G.H., et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006, 24:3187-3205.
9. National Comprehensive Cancer Network NCCN clinical practice guidelines in oncology™. Myeloid growth factors 2008, National Comprehensive Cancer Network, Jamestown, PA.
10. Greil R., Psenak O. Hematopoietic growth factors: ESMO recommendations for the application. Ann Oncol 2007, 18(Suppl. 2):ii89-ii91.
11. Gridelli C., Aapro M.S., Barni S., et al. Role of colony stimulating factors (CSFs) in solid tumours: results of an expert panel. Crit Rev Oncol Hematol 2007, 63:53-64.
12. Zielinski C.C., Awada A., Cameron D.A., Cufer T., Martin M., Aapro M. The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients. Eur J Cancer 2008, 44:353-365.
13. Muss H.B., Berry D.A., Cirrincione C., et al. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. J Clin Oncol 2007, 25:3699-3704.
14. Crivellari D., Bonetti M., Castiglione-Gertsch M., et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. J Clin Oncol 2000, 18:1412-1422.
15. Du X.L., Osborne C., Goodwin J.S. Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol 2002, 20:4636-4642.
16. Muss H.B., Woolf S., Berry D., et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 2005, 293:1073-1081.
17. Repetto L., Biganzoli L., Koehne C.H., et al. EORTC cancer in the elderly task force guidelines for the use of colony-stimulating factors in elderly patients with cancer. Eur J Cancer 2003, 39:2264-2272.
18. Bokemeyer C., Honecker F., Wedding U., Spath-Schwalbe E., Lipp H.P., Kolb G. Use of hematopoietic growth factors in elderly patients receiving cytotoxic chemotherapy. Onkologie 2002, 25:32-39.
19. Crivellari D., Aapro M., Leonard R., et al. Breast cancer in the elderly. J Clin Oncol 2007, 25:1882-1890.
20. Wildiers H., Kunkler I., Biganzoli L., et al. Management of breast cancer in the elderly: recommendations of the International Society of Geriatric Oncology (SIOG). Lancet Oncol 2007, 8:1101-1115.
21. von Minckwitz G., Schwenkglenks M., Skacel T., et al. Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropenia management: results from an integrated analysis. Eur J Cancer 2009, 45:608-617.
22. Schwenkglenks M., Jackisch C., Constenla M., et al. Neutropenic event risk and impaired chemotherapy delivery in six European audits of breast cancer treatment. Support Care Cancer 2006, 14:901-909.
23. von Minckwitz G., Kummel S., du B.A., et al. Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol 2008, 19:292-298.
24. Vogel C.L., Wojtukiewicz M.Z., Carroll R.R., et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005, 23:1178-1184.
25. Romieu G., Clemens M., Mahlberg R., et al. Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: a randomized phase 2 trial. Crit Rev Oncol Hematol 2007, 64:64-72.
26. Lichtman S.M., Wildiers H., Launay-Vacher V., Steer C., Chatelut E., Aapro M. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer 2007, 43:14-34.
27. Lichtman S.M., Wildiers H., Chatelut E., et al. International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients-an analysis of the medical literature. J Clin Oncol 2007, 25:1832-1843.
28. Shayne M., Culakova E., Poniewierski M.S., et al. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. Cancer 2007, 110:1611-1620.
29. Shayne M., Crawford J., Dale D.C., Culakova E., Lyman G.H. Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treat 2006, 100:255-262.
30. Lyman G.H., Dale D.C., Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 2003, 21:4524-4531.
31. Lyman G.H., Lyman C.H., Agboola O. Risk models for predicting chemotherapy-induced neutropenia. Oncologist 2005, 10:427-437.
32. Loibl S., von Minckwitz G., Harbeck N., et al. Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials. Breast Cancer Res 2008, 10:R77. [Epub ahead of print].
33. Crawford J., Dale D.C., Kuderer N.M., et al. Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw 2008, 6:109-118.
34. Pinto L., Liu Z., Doan Q., Bernal M., Dubois R., Lyman G. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr Med Res Opin 2007, 23:2283-2295.
35. Green M.D., Koebl H., Baselga J., et al. A randomized double-blind multicenter phase III study of fixed-dose single administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003, 14:29-35.